Trial Condition(s):

Carcinoma, Renal Cell

Nexavar dosing in renal cancer patients in "real-life" setting (NEXST)

Bayer Identifier:

16268

ClinicalTrials.gov Identifier:

NCT01557127

EudraCT Number:

Not Available

Study Completed

Trial Purpose

This study is a registry of renal cancer patients treated with Nexavar. It aims to evaluate the actual dosing of Nexavar in "real-life" setting vs. the prescribed dose.

Inclusion Criteria
- Age >/= 18 years
 - Diagnosis of renal cell carcinoma
 - Failure of prior therapy with interferon-alfa (IFN) or interleukine-2 (IL-2) or disqualified from therapy with IFN/IL-2
 - Patients in whom the oncologist has decide to start therapy with sorafenib.
Exclusion Criteria
-Synonymous with contraindications to Nexavar.

Trial Summary

Enrollment Goal
205
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Nexavar (Sorafenib, BAY43-9006)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Poland

Status
Completed
 

Trial Design